Aarti Drugs Limited Total Liabilities
Aarti Drugs Limited total liabilities. Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has total liabilities worth Rs12.66 Billion INR (≈ $136.92 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Aarti Drugs Limited to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aarti Drugs Limited (2006–2026)
Total liabilities of Aarti Drugs Limited from 2006 to 2026. This chart illustrates how Aarti Drugs Limited's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Aarti Drugs Limited to see how much of total assets are deployed in long-term investments.
Aarti Drugs Limited Competitors by Total Liabilities
The table below lists competitors of Aarti Drugs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing JCZ Technology Co. Ltd. A
SHG:688291
|
China | CN¥86.15 Million |
|
Eson Precision Ind Co Ltd
TW:5243
|
Taiwan | NT$5.47 Billion |
|
Dymatic Chemicals Inc
SHE:002054
|
China | CN¥3.43 Billion |
|
China Chippacking Technology Co. Ltd. A
SHG:688216
|
China | CN¥1.26 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$732.53 Million |
|
Everbright Jiabao Co Ltd
SHG:600622
|
China | CN¥16.59 Billion |
|
Viromed Medical AG
DU:Q11
|
Germany | €69.84 Million |
|
Gallant Precision Machining Co Ltd
TWO:5443
|
Taiwan | NT$7.62 Billion |
Liability Composition Analysis (2006–2026)
This chart breaks down Aarti Drugs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AARTIDRUGS asset base.
Liquidity & Leverage Metrics
Aarti Drugs Limited Total Liabilities Ratios Explained
Aarti Drugs Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aarti Drugs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aarti Drugs Limited (2006–2026)
The table below shows the annual total liabilities of Aarti Drugs Limited from 2006 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs12.66 Billion ≈ $136.92 Million |
+5.04% |
| 2025-03-31 | Rs12.05 Billion ≈ $130.35 Million |
+4.78% |
| 2024-03-31 | Rs11.50 Billion ≈ $124.41 Million |
-6.38% |
| 2023-03-31 | Rs12.29 Billion ≈ $132.88 Million |
+4.87% |
| 2022-03-31 | Rs11.72 Billion ≈ $126.71 Million |
+37.42% |
| 2021-03-31 | Rs8.53 Billion ≈ $92.21 Million |
-7.73% |
| 2020-03-31 | Rs9.24 Billion ≈ $99.93 Million |
+0.50% |
| 2019-03-31 | Rs9.19 Billion ≈ $99.43 Million |
-1.40% |
| 2018-03-31 | Rs9.33 Billion ≈ $100.85 Million |
+21.63% |
| 2017-03-31 | Rs7.67 Billion ≈ $82.91 Million |
+2.94% |
| 2016-03-31 | Rs7.45 Billion ≈ $80.55 Million |
+7.35% |
| 2015-03-31 | Rs6.94 Billion ≈ $75.03 Million |
+15.86% |
| 2014-03-31 | Rs5.99 Billion ≈ $64.76 Million |
+16.94% |
| 2013-03-31 | Rs5.12 Billion ≈ $55.38 Million |
+17.42% |
| 2012-03-31 | Rs4.36 Billion ≈ $47.17 Million |
+21.05% |
| 2011-03-31 | Rs3.60 Billion ≈ $38.97 Million |
+32.16% |
| 2010-03-31 | Rs2.73 Billion ≈ $29.48 Million |
-2.56% |
| 2009-03-31 | Rs2.80 Billion ≈ $30.26 Million |
-8.30% |
| 2008-03-31 | Rs3.05 Billion ≈ $33.00 Million |
+14.61% |
| 2007-03-31 | Rs2.66 Billion ≈ $28.79 Million |
-0.11% |
| 2006-03-31 | Rs2.66 Billion ≈ $28.82 Million |
-- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more